EP3089982A2 - Analogues 7-bêta d'orvinols - Google Patents

Analogues 7-bêta d'orvinols

Info

Publication number
EP3089982A2
EP3089982A2 EP14874386.7A EP14874386A EP3089982A2 EP 3089982 A2 EP3089982 A2 EP 3089982A2 EP 14874386 A EP14874386 A EP 14874386A EP 3089982 A2 EP3089982 A2 EP 3089982A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
membered
compound
halo
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14874386.7A
Other languages
German (de)
English (en)
Other versions
EP3089982A4 (fr
Inventor
Donald J. Kyle
Laykea Tafesse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of EP3089982A2 publication Critical patent/EP3089982A2/fr
Publication of EP3089982A4 publication Critical patent/EP3089982A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms

Definitions

  • the present disclosure provides Compounds of the Invention for use in modulation of one or more opioid receptors in a patient. In another aspect, the present disclosure provides use of Compounds of the Invention in the manufacture of a medicament for treating or preventing a disorder responsive to the modulation of one or more opioid receptors.
  • the present disclosure provides Compounds of the Invention for use as a medicament.
  • R 7 is selected from the group consisting of hydrogen, (Ci-C6)alkyl, (C2-C6)alkenyl, (C 2 -C 6 )alkynyl, (C 3 -Ci 2 )cycloalkyl, (C 4 -Ci 2 )cycloalkenyl, ((C 3 -Ci 2 )cycloalkyl)-(Ci-C 6 )alkyl-, and ((C 4 _Ci 2 )cycloalkenyl)-(Ci-C 6 )alkyl-;
  • R 9 and R 10 are each independently selected from the group consisting of hydrogen, (Ci-C 6 )alkyl, (C 2 _C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-Cio)alkoxy, (C 3 -Ci 2 )cycloalkyl, (C 3 - Ci 2 )cycloalkenyl, ((C 3 -Ci 2 )cycloalkyl)-(Ci-C 6 )alkyl-, and ((C 3 -Ci 2 )cycloalkenyl)-(Ci- C 6 )alkyl-;
  • R la or R lb is selected from the group consisting of CH 2 F and CH 2 C1.
  • Compounds of the Invention are compounds of any one of
  • Compounds of the Invention are compounds of any one of Formulae I-III, wherein Q is selected from the group consisting of OH, (Ci-C6)alkoxy, (6- to 10-membered)aryl, ((C 3 -C7)cycloalkyl)-(Ci-C4)alkyl-, ((6- to 10-membered)aryl)-(Ci- C 4 )alkyl-, -(OCH 2 CH 2 ) s -0(Ci-C 4 )alkyl, -(CH 2 CH 2 0) s -(C 1 -C 4 )alkyl,
  • Compounds of the Invention are compounds of any one of Formulae I-III, wherein Q is -(OCH 2 CH 2 ) s -0(Ci-C 6 )alkyl, -(CH 2 CH 2 0) s -(Ci-C 6 )alkyl, or - (OCH 2 CH 2 ) s -OH and s is 1, 2, 3, 4, 5, 6, or 7.
  • Q is -(OCH 2 CH 2 ) 5 OCH 3 or -(OCH 2 CH 2 ) 3 OCH 3 .
  • Compounds of the Invention are compounds of any one of
  • Compounds of the Invention are compounds of any one of
  • Compounds of the Invention are compounds of any one of Formulae I-III, wherein Z is -CH 2 - and Y is -CH.
  • Compounds of the Invention are compounds of any one of
  • Compounds of the Invention are compounds of any one of
  • Formulae I-II wherein Z is -CH 2 , Y absent, R 1 is ((C 3 -Ci 2 )cycloalkyl)-(Ci-C 6 )alkyl-, W 1 is (C 2 -C 6 )alkynyl, and at least one of R la and R lb is OH.
  • Compounds of the Invention are compounds of any one of Formulae I-III, wherein X is OH or NH 2 , then W 1 is selected from ((C 3 -Ci 2 )cycloalkyl)-(Ci- C 6 )alkyl-, ((3- to 12-membered)heterocycle)-(Ci-C6)alkyl-, ((6- to 12-membered)aryl)-(Ci- C 6 )alkyl-, ((5- to 12-membered)heteroaryl-(Ci-C6)alkyl-; any of which is optionally substituted.
  • Compounds of the Invention are compounds of Formula IV, wherein R 16 is selected from the group consisting of
  • Compounds of the Invention are compounds of Formula IV, wherein G is -NH- and R 15 is selected from the group consisting of -(OCH 2 CH 2 ) s -0(Ci- C 6 )alkyl,
  • (5- to 12- membered)carbocyclic ring refers to a bicyclic hydrocarbon ring system having from 5 to 12 carbon atoms, which is either saturated, unsaturated, non-aromatic or aromatic.
  • Useful aryl(C 2 _6)alkenyl groups include any of the above-mentioned C 2 -C 6 alkenyl groups substituted by any of the above-mentioned aryl groups (e.g., phenylethenyl).
  • Z is substituted means that Z is "-(CH 2 ) m -" and m is 1, 2,
  • a typical, non-limiting, process of preparing a solvate would involve dissolving a compound of any of Formulae I-V in a desired solvent (organic, water, or a mixture thereof) at temperatures above about 20 °C to about 25 °C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration.
  • a desired solvent organic, water, or a mixture thereof
  • Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
  • treating refers to administering a therapy in an amount, manner, or mode effective to improve a condition, symptom, or parameter associated with a disorder or to prevent progression of a disorder, to either a statistically significant degree or to a degree detectable to one skilled in the art.
  • An effective amount, manner, or mode can vary depending on the subject and may be tailored to the patient.
  • the Compound of the Invention is an agonist at one or more of the ⁇ , ⁇ and/or ⁇ opioid receptors.
  • the Compound of the Invention produces fewer side effects and/or less severe side effects than currently available analgesic opioid compounds when administered at doses producing equivalent levels of analgesia and/or anti-hyperalgesia.
  • the Compound of the Invention is an agonist at ORL-1 opioid receptor.
  • inflammatory diseases of the joints including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases, such as ileitis, ulcerative colitis, Barrett's syndrome, and Crohn's disease; inflammatory lung diseases, such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory diseases of the eye, including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory disease of the gum, including gingivitis and periodontitis; tuberculosis; leprosy; inflammatory diseases of the kidney, including uremic complications, glomerulonephritis and nephrosis; inflammatory disease of the skin, including sclerodermatitis, psoriasis and ecze
  • Compound O is prepared by reaction of Compound G with a suitable sulfonyl chloride (e.g., Compound N) in the presence of a suitable base (such as, TEA) in a suitable solvent (such as, DCM).
  • a suitable base such as, TEA
  • a suitable solvent such as, DCM
  • Compound O can be converted to Compound Q by reaction with a suitable amine (e.g., Compound P) in the presence of a suitable base (such as, DIPEA) in a suitable solvent (such as, CAN).
  • the prepared membrane solution (190 ⁇ /well) was transferred to 96-shallow well polypropylene plates containing 10 ⁇ of 20x concentrated stock solutions of the agonist [D-Ala 2 , N-methyl-Phe 4 Gly-ol 5 ] -enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C with shaking.
  • DAMGO dimethyl sulfoxide
  • U-2 OS cells expressing the recombinant human kappa opioid receptor ( ⁇ ) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl 2 , 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes from a cell line naturally expressing kappa opioid receptor can also be used. Membranes were collected by centrifugation at 30,000 x g for 15 min at 4°C and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of ⁇ receptor membranes were stored at -80 °C.
  • a Compound of the Invention can be delivered in a vesicle, in particular a liposome (see Langer, Science 249: 1527-1533 (1990); and Treat et al , Liposomes in the Therapy of Infectious Disease and Cancer 317-327 and 353-365 (1989)).
  • a Compound of the Invention can be delivered in an immediate release form. In other embodiments, a Compound of the Invention can be delivered in a controlled-release system or sustained-release system. Controlled- or sustained-release pharmaceutical compositions can have a common goal of improving drug therapy over the results achieved by their non-controlled or non-sustained-release counterparts. In one embodiment, a controlled- or sustained-release composition comprises a minimal amount of a Compound of the Invention to treat or prevent the Condition (or a symptom thereof) in a minimum amount of time. Advantages of controlled- or sustained- release compositions include extended activity of the drug, reduced dosage frequency, and increased compliance.
  • the amount effective for inhibiting or activating the ⁇ - opioid receptors function in a cell can typically range from about 10 "12 mol/L to about 10 "4 mol/L, or from about 10 " 12 mol/L to about 10 "5 mol/L, or from about 10 " 12 mol/L to about 10 "6 mol/L, or from about 10 "12 mol/L to about 10 "9 mol/L of a solution or suspension of the Compound of the Invention in a pharmaceutically acceptable carrier or excipient.
  • Compound 21 was then converted to Compound 22 in a manner similar to that described in Example 2 for the conversion of Compound 4 to Compound 5.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule I (I) et leurs sels et solvats pharmaceutiquement acceptables, où R1, R1a, R1b, X, Y, Z, G, Q, W1 et W2 sont tels que définis dans la description. L'invention concerne également l'utilisation des composés de formule I et de leurs sels et solvats pharmaceutiquement acceptables pour traiter des troubles réagissant à la modulation d'un ou plusieurs récepteurs opioïdes, ou comme intermédiaires synthétiques. Certains composés de la présente invention sont notamment utiles pour traiter la douleur.
EP14874386.7A 2013-12-26 2014-12-17 Analogues 7-bêta d'orvinols Withdrawn EP3089982A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920935P 2013-12-26 2013-12-26
US201461985812P 2014-04-29 2014-04-29
PCT/US2014/070765 WO2015100092A2 (fr) 2013-12-26 2014-12-17 Analogues 7-bêta d'orvinols

Publications (2)

Publication Number Publication Date
EP3089982A2 true EP3089982A2 (fr) 2016-11-09
EP3089982A4 EP3089982A4 (fr) 2017-09-27

Family

ID=53479768

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14874386.7A Withdrawn EP3089982A4 (fr) 2013-12-26 2014-12-17 Analogues 7-bêta d'orvinols

Country Status (3)

Country Link
US (1) US20160333020A1 (fr)
EP (1) EP3089982A4 (fr)
WO (1) WO2015100092A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566828T3 (es) 2010-09-21 2016-04-15 Purdue Pharma L.P. Análogos de buprenorfina como agonistas y/o antagonistas del receptor opioide
EP2917182B1 (fr) 2012-11-09 2018-01-03 Purdue Pharma LP Analogues de benzomorphane et leur utilisation
WO2015097545A1 (fr) 2013-12-26 2015-07-02 Purdue Pharma L.P. Morphinanes oxabicyclo[2.2.2]octane modulateurs des récepteurs aux opiacés
EP3087057A4 (fr) 2013-12-26 2017-06-28 Purdue Pharma LP Morphinanes à cycle contracté et leur utilisation
WO2015097548A1 (fr) 2013-12-26 2015-07-02 Purdue Pharma L.P. Analogues 7-bêta-alkyle d'orvinols
WO2015097547A1 (fr) 2013-12-26 2015-07-02 Purdue Pharma L.P. Hydantoïnes de morphinane substitués en position 10
WO2015099863A1 (fr) 2013-12-27 2015-07-02 Purdue Pharma L.P. Analogues de la morphinane 6-substitués et 7-substitués, et leurs utilisations
EP3089978B1 (fr) 2013-12-30 2018-08-29 Purdue Pharma L.P. Analogues de morphinane pyridone-sulfones utilisés comme ligands de récepteurs opioïdes
CA2950567A1 (fr) 2014-05-27 2015-12-03 Purdue Pharma L.P. Morphinanes spirocycliques et utilisation associee
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (fr) 2017-01-02 2018-07-05 Purdue Pharma L.P. Dérivés de morphinane et leur utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562279A (en) * 1969-05-15 1971-02-09 American Cyanamid Co Substituted 7,8-dihydro - 6 - methoxy-6,14-endo(etheno or ethano)morphide - 7-ketones and n-cycloalkylmethyl - 7,8-dihydro - 6 - methoxy-6,14-endo(etheno or ethano) norcodide-7-ketones
ES2449222T3 (es) * 2008-07-30 2014-03-18 Purdue Pharma Lp Análogos de buprenorfina
US8232397B2 (en) * 2008-09-30 2012-07-31 Mallinckrodt Llc Processes for the production of buprenorphine with reduced impurity formation
ES2566828T3 (es) * 2010-09-21 2016-04-15 Purdue Pharma L.P. Análogos de buprenorfina como agonistas y/o antagonistas del receptor opioide

Also Published As

Publication number Publication date
EP3089982A4 (fr) 2017-09-27
WO2015100092A3 (fr) 2015-10-29
WO2015100092A2 (fr) 2015-07-02
US20160333020A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
EP3087078B1 (fr) Analogues 7-bêta-alkyle d'orvinols
CA2894971C (fr) Derives de morphinane contenant de l'azote et leur utilisation
WO2015100092A2 (fr) Analogues 7-bêta d'orvinols
EP2931726B1 (fr) Morphinanes spirocycliques et leur utilisation
EP3087079B1 (fr) Morphinanes oxabicyclo[2.2.2]octane modulateurs des récepteurs aux opiacés
US10131666B2 (en) Heterocyclic morphinan derivatives and use thereof
WO2015100174A1 (fr) Morphinanes à cycle contracté et leur utilisation
EP2941430A1 (fr) Analogues de 7,8-cyclicmorphinane
WO2015192053A1 (fr) Dérivés d'azamophinan et leur utilisation
AU2013308174A1 (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
EP2941431A1 (fr) Morphinanes substitués et utilisation de ceux-ci
US10030021B2 (en) Spirocyclic morphinans and use thereof
WO2015097546A1 (fr) Composés à base de propellane et utilisation de ces derniers en qualité de modulateurs de récepteurs d'opioïdes
EP3089978A1 (fr) Analogues de morphinane pyridone-sulfones utilisés comme ligands de récepteurs opioïdes
WO2015097547A1 (fr) Hydantoïnes de morphinane substitués en position 10

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160721

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 489/02 20060101ALI20161010BHEP

Ipc: A61K 31/485 20060101AFI20161010BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KYLE, DONALD J.

Inventor name: TAFESSE, LAYKEA

A4 Supplementary search report drawn up and despatched

Effective date: 20170828

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/485 20060101AFI20170822BHEP

Ipc: C07D 489/12 20060101ALI20170822BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190618